Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
absorbed acellular diphtheria-tetanus-pertussis (component) combined vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Luzhu Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The absorbed acellular diphtheria-tetanus-pertussis (component) combined vaccine is a trivalent vaccine developed by Beijing Zhifei Luzhu Biopharmaceutical. Unlike traditional co-purified DTaP vaccines, this 'component' vaccine (DTaP-cp) is formulated with purified individual antigens, typically including diphtheria toxoid, tetanus toxoid, and specific acellular pertussis antigens such as pertussis toxoid (PT) and filamentous hemagglutinin (FHA), adsorbed onto an aluminum-based adjuvant. It is intended for the active immunization of infants and children against diphtheria, tetanus, and pertussis (whooping cough). As of 2023, the vaccine is undergoing Phase III clinical evaluation in China to assess its safety and immunogenicity in a primary and booster vaccination schedule.
- Other names
- absorbed acellular diphtheria-tetanus-pertussis combined vaccineDTaP-cp vaccine吸附无细胞百白破（组分）联合疫苗
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)Diphtheria toxinFIM2/FIM3 (Bordetella pertussis fimbriae 2/3)
Beyond the preview
Go deeper on absorbed acellular diphtheria-tetanus-pertussis (component) combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on absorbed acellular diphtheria-tetanus-pertussis (component) combined vaccine.